Viralgen has developed a new technology called Pro10™ cell line to improve the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy production. This proprietary mammalian suspension technology enables scalable and robust production of rAAV, addressing large-scale production challenges in AAV gene therapies.

The Pro10™ animal component suspension cell line derived from HEK293 has been fully characterized and licensed for gene therapy development by other biopharmaceutical companies. These cells were optimized for rAAV production and were successfully scaled up to 2000L, showing consistent and reproducible cell growth rates. They show similar productivity in small and large bioreactors and can produce different AAV serotypes.

Pro10™ cells play a key role in Viralgen’s AAV vector production platform process and have been vital in the production of breakthrough gene therapies. The Pro10™ animal component suspension cell line is fully described in PDF, highlighting its ability to reduce process development time and cost. This innovative technology is a promising advance in the field of gene therapy production, offering a solution to the challenges facing large-scale production of AAV vectors.

By Samantha Johnson

As a dedicated content writer at, I immerse myself in the art of storytelling through words. With a keen eye for detail and a passion for crafting engaging narratives, I strive to captivate our audience with each piece I create. Whether I'm covering breaking news, delving into feature articles, or exploring thought-provoking editorials, my goal remains constant: to inform, entertain, and inspire through the power of writing. Join me on this journalistic journey as we navigate through the ever-evolving media landscape together.

Leave a Reply